A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3 - Related Studies

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

This study has been completed.

Study NCT00000779. Last updated on June 23, 2005. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Infection

3	More general conditions related to this trial
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Aluminum hydroxide
		MF59
		rgp120/HIV-1IIIB
		rgp120/HIV-1MN
		rgp120/HIV-1 SF-2
		Env 2-3

5	More general drug interventions related to this trial
		Adjuvants, Immunologic
		Antacids
		Immunologic Factors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs

6	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)